Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) and Surrozen (NASDAQ:SRZN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.
Volatility and Risk
Tectonic Therapeutic has a beta of 2.63, suggesting that its share price is 163% more volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.
Valuation & Earnings
This table compares Tectonic Therapeutic and Surrozen”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tectonic Therapeutic | N/A | N/A | $12.16 million | ($5.89) | -7.94 |
| Surrozen | $12.50 million | 2.94 | -$43.04 million | N/A | N/A |
Profitability
This table compares Tectonic Therapeutic and Surrozen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tectonic Therapeutic | N/A | -35.53% | -31.97% |
| Surrozen | N/A | -120.51% | -54.68% |
Insider & Institutional Ownership
62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 9.2% of Tectonic Therapeutic shares are held by insiders. Comparatively, 43.5% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Tectonic Therapeutic and Surrozen, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tectonic Therapeutic | 0 | 0 | 5 | 1 | 3.17 |
| Surrozen | 0 | 0 | 1 | 0 | 3.00 |
Tectonic Therapeutic presently has a consensus target price of $72.25, indicating a potential upside of 54.58%. Surrozen has a consensus target price of $45.00, indicating a potential upside of 298.23%. Given Surrozen’s higher possible upside, analysts clearly believe Surrozen is more favorable than Tectonic Therapeutic.
Summary
Tectonic Therapeutic beats Surrozen on 7 of the 11 factors compared between the two stocks.
About Tectonic Therapeutic
Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.
About Surrozen
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.
